A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours

Bibliography

• FOLKMAN J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. (1971) 285(21):1182-1186.
   PubMed Web of Science ®Google Scholar
• LEUNG DW, CACHIANES G, KUANG WJ, GOEDDEL DV, FERRARA N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 246(4935):1306-1309.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350(23):2335-2342.
   PubMed Web of Science ®Google Scholar
• JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small- cell lung cancer. J. Clin. Oncol. (2004) 22(11):2184-2191.
   PubMed Web of Science ®Google Scholar
• MILLER KD: E2100: a randomized Phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. ASCO, Orlando, USA (16 May 2005).
   Google Scholar
• RATAIN MJ, EISEN T, STADLER WM et al.: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(16):2505-2512.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, MICHAELSON MD, REDMAN BG et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(1):16-24.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, RINI BI, BUKOWSKI RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 295(21):2516-2524.
   PubMed Web of Science ®Google Scholar
• DEMETRI GD, VAN OOSTEROM AT, GARRETT CR et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 368(9544):1329-1338.
   PubMed Web of Science ®Google Scholar
• TERRIS B, SCOAZEC JY, RUBBIA L et al.: Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology (1998) 32(2):133-138.
   PubMed Web of Science ®Google Scholar
• LA ROSA S, UCCELLA S, FINZI G, ALBARELLO L, SESSA F, CAPELLA C: Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum. Pathol. (2003) 34(1):18-27.
   PubMed Web of Science ®Google Scholar
• PAVEL ME, HASSLER G, BAUM U, HAHN EG, LOHMANN T, SCHUPPAN D: Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin. Endocrinol. (Oxf.) (2005) 62(4):434-443.
   PubMed Web of Science ®Google Scholar
• YAO J, NG C, HOFF P, PHAN T, HESS K: Improved progression free survival (PFS) and rapid sustained decreased perfusion among patients with advanced carcinoid treated with bevacizumab. J. Clin. Oncol. Suppl. (2005) 23(16S):4007 (Abstract).
   Google Scholar
• YAO J, CHARNASANGAVEJ S, FARIA J, SZKLARUK H: Rapid decrease in blood flow (BF), blood volume (BV), and vascular permeability (PS) in carcinoid patients treated with bevacizumab. J. Clin. Oncol. (2004) 22(14S):3013 (Abstract).
   Google Scholar
• KULKE M, BERGSLAND E, RYAN D: A Phase II study to evaluate the safety and efficacy of SU11248 in patients with unresectable neuroendocrine tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:A958.
   Google Scholar
• LAMBERTS SW, VAN DER LELY AJ, DE HERDER WW, HOFLAND LJ: Octreotide. N. Engl. J. Med. (1996) 334(4):246-254.
   PubMed Web of Science ®Google Scholar
• REICHLIN S: Somatostatin. N. Engl. J. Med. (1983) 309(24):1495-1501.
   PubMed Web of Science ®Google Scholar
• PATEL YC, GREENWOOD MT, PANETTA R, DEMCHYSHYN L, NIZNIK H, SRIKANT CB: The somatostatin receptor family. Life Sci. (1995) 57(13):1249-1265.
   PubMed Web of Science ®Google Scholar
• GUILLERMET-GUIBERT J, LAHLOU H, CORDELIER P, BOUSQUET C, PYRONNET S, SUSINI C: Physiology of somatostatin receptors. J. Endocrinol. Invest. (2005) 28(Suppl. 11):5-9.
   PubMedGoogle Scholar
• GUILLERMET-GUIBERT J, LAHLOU H, PYRONNET S, BOUSQUET C, SUSINI C: Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects. Best Pract. Res.Clin. Gastroenterol. (2005) 19(4):535-551.
   PubMed Web of Science ®Google Scholar
• OBERG K, KVOLS LK, CAPLIN M et al.: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann. Oncol. (2004) 15(6):966-973.
   PubMed Web of Science ®Google Scholar
• WYMENGA AN, ERIKSSON B, SALMELA PI et al.: Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J. Clin. Oncol. (1999) 17(4):1111.
   PubMed Web of Science ®Google Scholar
• KVOLS LK, MOERTEL CG, O’CONNELL MJ, SCHUTT AJ, RUBIN J, HAHN RG: Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N. Engl. J. Med. (1986) 315(11):663-666.
   PubMed Web of Science ®Google Scholar
• O’DORISIO TM, MEKHJIAN HS, GAGINELLA TS: Medical therapy of VIPomas. Endocrinol. Metab. Clin. North Am. (1989) 18(2):545-556.
   PubMed Web of Science ®Google Scholar
• BODEN G, RYAN IG, EISENSCHMID BL, SHELMET JJ, OWEN OE: Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995. N. Engl. J. Med. (1986) 314(26):1686-1689.
   PubMed Web of Science ®Google Scholar
• ARNOLD R, TRAUTMANN ME, CREUTZFELDT W et al.: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut (1996) 38(3):430-438.
   PubMed Web of Science ®Google Scholar
• LAMBERTS SW, VAN DER LELY AJ, HOFLAND LJ: New somatostatin analogs: will they fulfill old promises? Eur. J. Endocrinol. (2002) 146(5):701-705.
   PubMed Web of Science ®Google Scholar
• BRUNS C, LEWIS I, BRINER U, MENO-TETANG G, WECKBECKER G: SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. (2002) 146(5):707-716.
   PubMed Web of Science ®Google Scholar
• BOERLIN V, VAN DER HOEK J, BEGLINGER C et al.: New insights on SOM230, a universal somatostatin receptor ligand. J. Endocrinol. Invest. (2003) 26(Suppl. 8):14-16.
   PubMedGoogle Scholar
• KVOLS LK, WIEDENMANN K, OBERG J: Safety and efficacy of pasireotide (SOM 230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a Phase II Study. GI ASCO, San Francisco, USA (2006) (Abstract 171).
   Google Scholar
• VALKEMA R, DE JONG M, BAKKER WH et al.: Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin. Nucl. Med. (2002) 32(2):110-122.
   PubMed Web of Science ®Google Scholar
• ANTHONY LB, WOLTERING EA, ESPENAN GD, CRONIN MD, MALONEY TJ, McCARTHY KE: Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin. Nucl. Med. (2002) 32(2):123-132.
   PubMed Web of Science ®Google Scholar
• WALDHERR C, PLESS M, MAECKE HR, HALDEMANN A, MUELLER-BRAND J: The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical Phase II study. Ann. Oncol. (2001) 12(7):941-945.
   PubMed Web of Science ®Google Scholar
• WALDHERR C, PLESS M, MAECKE HR et al.: Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J. Nucl. Med. (2002) 43(5):610-616.
   PubMed Web of Science ®Google Scholar
• PAGANELLI G, ZOBOLI S, CREMONESI M et al.: Receptor- mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur. J. Nucl. Med. (2001) 28(4):426-434.
   PubMedGoogle Scholar
• KWEKKEBOOM DJ, MUELLER-BRAND J, PAGANELLI G et al.: Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J. Nucl. Med. (2005) 46(Suppl. 1):62S-66S.
   PubMed Web of Science ®Google Scholar
• VALKEMA R, PAUWELS SA, KVOLS LK et al.: Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate. J. Nucl. Med. (2005) 46(Suppl. 1):83S-91S.
   PubMed Web of Science ®Google Scholar
• REUBI JC, SCHAR JC, WASER B et al.: Affinity profiles for human somatostatin receptor subtypes SST1 – SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. (2000) 27(3):273-282.
   PubMedGoogle Scholar
• KWEKKEBOOM DJ, BAKKER WH, KOOIJ PP et al.: [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur. J. Nucl. Med. (2001) 28(9):1319-1325.
   PubMedGoogle Scholar
• KWEKKEBOOM DJ, TEUNISSEN JJ, BAKKER WH et al.: Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. (2005) 23(12):2754-2762.
   PubMed Web of Science ®Google Scholar
• BJORNSTI MA, HOUGHTON PJ: The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer (2004) 4(5):335-348.
   PubMed Web of Science ®Google Scholar
• LAW M, FORRESTER E, CHYTIL A et al.: Rapamycin disrupts cyclin/cyclin- dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res. (2006) 66(2):1070-1080.
   PubMed Web of Science ®Google Scholar
• MITA MM, MITA A, ROWINSKY EK: Mammalian target of rapamycin: a new molecular target for breast cancer. Clin. Breast Cancer (2003) 4(2):126-137.
   PubMedGoogle Scholar
• YAO JC, PHAN AT, CHANG DZ et al.: Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET). J. Clin. Oncol. (2006) 24(18S):4042.
   PubMed Web of Science ®Google Scholar
• MOERTEL CG, KVOLS LK, O’CONNELL MJ, RUBIN J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer (1991) 68(2):227-232.
   PubMed Web of Science ®Google Scholar
• MOERTEL CG, HANLEY JA: Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin. Trials (1979) 2(4):327-334.
   PubMedGoogle Scholar
• ENGSTROM PF, LAVIN PT, MOERTEL CG, FOLSCH E, DOUGLASS HO Jr: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J. Clin. Oncol. (1984) 2(11):1255-1259.
   PubMed Web of Science ®Google Scholar
• MURRAY-LYON IM, EDDLESTON AL, WILLIAMS R et al.: Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet (1968) 2(7574):895-898.
   PubMed Web of Science ®Google Scholar
• MOERTEL CG, HANLEY JA, JOHNSON LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. (1980) 303(21):1189-1194.
   PubMed Web of Science ®Google Scholar
• MOERTEL CG, LEFKOPOULO M, LIPSITZ S, HAHN RG, KLAASSEN D: Streptozocin–doxorubicin, streptozocin–fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. (1992) 326(8):519-523.
   PubMed Web of Science ®Google Scholar
• RAMANATHAN RK, CNAAN A, HAHN RG, CARBONE PP, HALLER DG: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann. Oncol. (2001) 12(8):1139-1143.
   PubMed Web of Science ®Google Scholar
• KOUVARAKI MA, AJANI JA, HOFF P et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol. (2004) 22(23):4762-4771.
   PubMed Web of Science ®Google Scholar
• KULKE MH, STUART K, ENZINGER PC et al.: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol. (2006) 24(3):401-406.
   PubMed Web of Science ®Google Scholar
• FINE R, FOGELMAN D, SCHREIBMAN S: Effective treatment of neuroendocrine tumors with capecitabine and temozolomide. ASCO, Orlando, USA (16 May 2005):4216 (Abstract).
   Google Scholar